Abstract Purpose: Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of various cancers including breast cancer. Many epigenetically inactivated genes involved in breast cancer development remain to be identified. Therefore, in this study we used a pharmacologic unmasking approach in breast cancer cell lines with 5-aza-2 ¶-deoxycytidine (5-aza-dC) followed by microarray expression analysis to identify epigenetically inactivated genes in breast cancer. Experimental Design: Breast cancer cell lines were treated with 5-aza-dC followed by microarray analysis to identify epigenetically inactivated genes in breast cancer. We then used bisulfite DNA sequencing, conventional methylation-specific PCR, and quantitative fluorogenic real-time methylation-specific PCR to confirm cancer-specific methylation in novel genes. Results: Forty-nine genes were up-regulated in breast cancer cells lines after 5-aza-dC treatment, as determined by microarray analysis. Five genes (MAL, FKBP4,VGF, OGDHL, and KIF1A) showed cancer-specific methylation in breast tissues. Methylation of at least two was found at high frequency only in breast cancers (40 of 40) as compared with normal breast tissue (0 of 10; P < 0.0001, Fisher's exact test).
Breast cancer is second to lung cancer as the leading cause of cancer death among women (1) . According to the WHO, more than 1.2 million women worldwide will be diagnosed with breast cancer this year. The limitations of mammography have been documented (2, 3) especially for those women with premenopausal breast cancer. Suspicious lesions detected on mammography are analyzed by fine needle aspiration biopsy. However, the accuracy of cytomorphologic analysis relies mostly on the expertise of the pathologist, which has shown to have a false negative rate of 5% to 30% (4) . The search for more sensitive and specific tests is ongoing. One approach is the identification of breast cancer -specific biomarkers and noninvasive methods for the detection of these biomarkers at an early stage (5 -8) .
Alterations in various genes that positively and negatively regulate cell function are involved in tumorigenesis (9) . Many factors can affect gene function, including genetic alterations as well as epigenetic modifications. Epigenetic changes such as DNA methylation are some of the most common molecular alterations in human neoplasia (10 -13) . DNA hypermethylation refers to the addition of a methyl group to the cytosine ring of those cytosines that precede a guanosine (referred to as CpG dinucleotides) to form methyl cytosine (5-methylcytosine). CpG dinucleotides are found at increased frequency in the promoter region of many genes. These CpGs are referred to as ''CpG islands.'' Methylation of these islands in the promoter region is frequently associated with reduced gene expression (12) . Several tumor suppressor genes contain CpG islands in their promoters, and many of them show evidence of methylation silencing (14) . Aberrant promoter methylation may affect genes involved in cell cycle control, DNA repair, cell adhesion, signal transduction, apoptosis, and cell differentiation (13 -16) . Epigenetic changes are an early event in carcinogenesis and are present in the precursor lesions of a variety of cancers including breast (17) , lung (18) , and colon (19) . A summary list of hypermethylated genes in breast cancer can be found in ref. 20 ; many of these genes were found at low frequency (14) whereas others showed methylation in normal tissues as well (21) .
Although the number of hypermethylated genes in cancer is growing by testing candidate genes (i.e., methylation of known tumor suppressor genes in other cancer types), many epigenetically modified genes remain to be elucidated. Some authors suggest (22, 23) a range of 100 to 400 promoter hypermethylated CpG islands in a given tumor type, suggesting that other epigenetically inactivated genes involved in breast cancer development remain to be identified. We used pharmacologic unmasking of breast cancer cell lines with 5-aza-2 ¶-deoxycytidine (5-aza-dC) followed by expression microarray analysis to identify epigenetically inactivated genes in breast cancer. We then used bisulfite DNA sequencing, conventional methylation-specific PCR (MSP), and quantitative MSP to confirm breast cancer -specific methylation in novel genes. We found five promising cancer-specific methylated genes that shed light on the biology of breast cancer and may aid in diagnostic approaches.
Materials and Methods
Cell lines. We used five different human breast cancer cell lines (BT-20, MCF-7, MDA-MB-231, Hs578T, and MDA-MB-436). Cell lines were propagated in accordance with the instructions from American Type Culture Collection.
5-Aza-dC treatment of cells. Cell lines were treated with 5-aza-dC as previously described (24) . Briefly, we seeded all cell lines (1 Â 10 6 ) in their respective culture medium and maintained them for 24 h before treating them with 5 Amol/L 5-aza-dC (Sigma) for 3 d. We renewed medium containing 5-aza-dC every 24 h during the treatment. We handled control cells the same way, without adding 5-aza-dC. Stock solutions of 5-aza-dC were dissolved in PBS (pH 7.5). We prepared total RNA using the RNeasy Mini Kit (Qiagen).
Microarray. Affymetrix arrays were used for gene expression profiling per the manufacturer's instruction. We used GeneChip Human Genome U133A Arrays containing >22,000 probe sets for analysis of >18,400 transcripts, which include f14,500 well-characterized human genes. Biotinylated RNA probe preparation and hybridization were previously described (24) .
Analysis of expression data. We computed gene expression summary values for Affymetrix GeneChip data using the bioconductor package (which uses background adjustment, quantile normalization, and summarization; ref. 25) .
Tissue samples and DNA extraction. We evaluated tissue samples from primary breast cancers (total 40 human samples). Tissue samples from 10 age-matched individuals without a history of malignancy were used as controls. The demographics of patient samples are listed in Table 1 . Tissue samples were microdissected to isolate more than 70% epithelial cells in both neoplastic and nonneoplastic tissues. Cell pellets were digested with 1% SDS and 50 Ag/mL proteinase K (Boehringer Mannheim) at 48jC overnight, followed by phenol/ chloroform extraction and ethanol precipitation of DNA as previously described (26) .
Bisulfite genomic sequence analysis, conventional MSP, and quantitative MSP. Bisulfite sequence analysis was done to determine the methylation status in cell lines and a limited number of tissues including primary tumors and age-matched normal controls from the same organ. We extracted genomic DNA as above and carried out bisulfite modification of genomic DNA as described previously (27) . Bisulfite-treated DNA was amplified for the 5 ¶ region that included at least a portion of the CpG island within 1 kb of the proposed
Translational Relevance
The novel methylation markers of breast cancer discovered in this study show great potential in molecular detection approaches. These markers can be detected in stage I breast cancers and therefore show promise in the early detection of breast cancer.The development of a blood-based test for breast cancer based on gene promoter methylation of these markers could augment current early detection approaches such as mammography. Moreover, methylated targets also have real therapeutic potential with the continuing development of demethylating agents that can be used in the clinic. transcriptional start site using primer sets (Supplementary Table S1 ). The primers for bisulfite sequencing were designed to hybridize to regions in the promoter without CpG dinucleotides. PCR products were gel-purified using the QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer's instructions. Each amplified DNA sample was sequenced by the Applied Biosystems 3700 DNA analyzer using nested, forward, or reverse primers and BD terminator dye (Applied Biosystems). When necessary, MSP primers were designed to amplify methylated or unmethylated DNA.
For high-throughput analysis, we developed quantitative MSP for five genes. Briefly, bisulfite-modified DNA was used as template for fluorescence-based real-time PCR, as previously described (28) . Amplification reactions were carried out in triplicate using 3 AL bisulfite-modified DNA. Primers and probes were designed to specifically amplify the promoters of the five genes of interest and the promoter of a reference gene, actin-B (ACTB). Primer and probe sequences and annealing temperatures are provided in Supplementary Table S2 . Amplification reactions were carried out in 384-well plates in a 7900 Sequence Detector (Perkin-Elmer Applied Biosystems) and were analyzed by SDS 2.2.1 (Sequence Detector System; Applied Biosystems). Each plate included patient DNA samples, positive (in vitro methylated leukocyte DNA) and negative (normal leukocyte DNA or DNA from a known unmethylated cell line) controls, and multiple water blanks. Leukocyte DNA was methylated in vitro with excess SssI methyltransferase (New England Biolabs, Inc.) to generate completely methylated DNA. Serial dilutions (90-0.009 ng) of this DNA were used to construct a calibration curve for each plate. The relative level of methylated DNA for each gene in each sample was determined as a ratio of MSP for the amplified gene to ACTB and then multiplied by 1,000 for easier tabulation [(average value of triplicates of gene of interest / average value of triplicates of ACTB) Â 1,000]. The samples were categorized as unmethylated or methylated based on detection of methylation above a threshold set for each gene. This threshold was determined by analyzing the levels and distribution of methylation, if any, in normal (nonneoplastic) age-matched tissues. -20) . Genes that were methylated in cell lines were then bisulfite sequenced in 10 normal breast tissues and 10 breast tumors. GALE, KRT14, HMG20B, NDP, and WDR45 showed tissue-specific methylation, whereas MAL, FKBP4, KIF1A, OGDHL, and VGF were methylated in a cancer-specific manner. Reverse transcription-PCR. RNA was extracted from 5-aza-dCtreated as well as untreated breast cancer cell lines. Briefly, RNA was extracted using Trizol (Invitrogen). Four micrograms of total RNA were reverse transcribed with Superscript II reverse transcriptase (Invitrogen), then cDNA was amplified by PCR. Primer sequences and PCR conditions are available in Supplementary Table S3 . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The PCR products were separated by agarose gel electrophoresis.
Results
Validation of microarray data using cell lines. Microarray analysis in five human breast cancer cell lines (BT-20, MCF-7, MDA-MB-231, Hs578T, and MDA-MB-436) identified 49 potential gene targets based on reactivation after treatment with 5-aza-dC. Of these 49 genes, two were not CpG rich, and seven were already known to harbor cancer-specific methylation after a literature search. Two genes were previously described by us (24) as methylated in breast cancer (KIF1A and OGDHL). The remaining 38 genes were validated in breast cancer cell lines (Table 2) . Primers were designed for each gene and tested by bisulfite sequence analysis and/or MSP in one or more cell line that exhibited reexpression after demethylation treatment. Promoter methylation of 9 genes (9 of 38, 24%) was documented based on identification of z50% methylated CpG sites in the CpG Island (Table 2 ). Reverse transcription-PCR was done to confirm up-regulation of candidate genes after 5-aza-dC treatment (Fig. 1) .
Promoter hypermethylation in normal and primary tumor tissues. To determine if the methylated genes in cancer cell lines were cancer specific, we investigated promoter methylation in a limited number (n f 10 for tumors, n f 5 for normal tissues) of various primary tumors and age-matched normal tissues by bisulfite sequence analysis and/or MSP ( Table 2 ). Of 9 genes that showed methylation in cell lines, promoter methylation was detected in 7 (78%) genes in primary tumor tissues. After testing corresponding age-matched normal tissues, 3 of these genes were identified to be methylated only in the neoplastic cells of primary tumors. Thus, 3 of 38 (8%) new potential cancer-specific methylated genes were identified.
The three cancer-specific methylated genes identified were MAL, FKBP4, and VGF. To determine the frequency of methylation in a larger set of samples, primers and probes for quantitative MSP were designed for these genes based on bisulfite sequencing data. Breast tumors (f40) and normal breast tissues (f10) were tested for methylation of these Fig. 2 ; Table 3 ).
Two of the genes identified by microarray analysis have been previously described by us (24) to show cancer-specific (20) (Table 3) .
Of 40 breast tumors that were tested for methylation of all five genes, all 40 (100%) had at least two of the five genes methylated. In 21 of 40 (53%) of the breast tumors cases, at least three of these genes were methylated and 10 of 40 (25%) showed methylation of four or more genes. Only two normal samples showed methylation in any of these genes (BN4 and BN7 for KIF1A; Table 4 ).
Discussion
Novel genes as markers for tumors. The ''candidate gene'' approach, where a tumor suppressor or previously reported methylated gene is tested in another type of cancer, has been used in most studies on DNA methylation in cancer. Our study involved identifying novel cancer-specific methylated genes based on a proven pharmacologic unmasking strategy in combination with a relatively large expression microarray. Among a large number of reexpressed candidate genes, we discovered three new cancer-specific methylated genes (MAL, FKBP4, and VGF).
The frequency of methylation of particular gene in primary tumors is less than that observed in cell lines (Table 3) . This is consistent with previous studies (29 -31) . In artificial conditions, cell lines may have acquired methylation of some genes to provide a cell growth advantage. It is also possible that some of our tissue samples may have been contaminated with unmethylated DNA from normal surrounding cells despite microdissection. Furthermore, the microarray reexpression predicted the presence of up to 38 methylated genes, whereas experimentally, 9 methylated genes in cell lines were identified. We may have missed a few genes due to the analysis of limited promoter regions (f200-300 bp for most of the genes) by bisulfite sequencing or MSP.
FKBP4 expression did not increase substantially after treatment of cell lines with demethylating agents. In some methylated promoters, the addition of histone deacetylase inhibitors and other combinational approaches has led to a more robust increase in expression. In searching for markers of early cancer detection and prognosis, promoter methylation need not necessarily correlate with severely reduced expression (Fig. 1) as long as the methylation pattern is specific to neoplastic cells (Table 3 ) and is associated with clinically important information (24, 32) .
In our cohort of breast tumors samples, MAL was found to be an excellent breast tumor marker, showing a high promoter methylation frequency (95%) in primary tumor samples. MAL is located at the 2cen-q13 locus of chromosome 2 and is a T-cell differentiation antigen. MAL expression was found to be downregulated in patients harboring esophageal squamous cell carcinoma (33) . MAL has also shown tumor-specific methylation in colon cancer (34) . MAL is a candidate tumor suppressor gene because it has been shown that MAL gene expression in esophageal cancer suppresses motility, invasion, and tumorigenicity and enhances apoptosis through the Fas pathway (35) . It is thus likely that MAL inactivation is an important step in the progression to cancer based on its high frequency of cancer-specific methylation in various tumor types and its tumor-suppressive activity.
Another gene found to be methylated in breast cancer is FKBP, with a moderate frequency (41%) and absence of methylation in normal breast tissues. FKBP4 is an immunophilin that possesses peptidyl-prolyl cis-trans isomerase activity and is a component of a subclass of steroid receptor complexes (36) . It acts as a cochaperone that binds to heat shock protein 90 to regulate the maturation of steroid hormone receptor. Studies have shown that FKBP4 acts as an androgen receptor folding factor and, accordingly, plays an important role in the androgen receptor signaling pathway (36) . The phenotype of male FKBP4-null mice is characterized by several defects in productive tissues consistent with androgen insensitivity. Knockdown of FKBP4 expression in HeLa cells decreases androgen receptor protein and reduces hormonal efficacy (37) . FKBP4 mRNA expression is increased MCF-7 cells (estrogen receptor positive) but not in MDA-MB-231 (estrogen receptor negative) cells (38) . This increase in expression in MCF-7 cells is due to an increase in mRNA stability. This increase is activated by estradiols in MCF-7 (estrogen receptor positive) breast cancer cell lines (39). Ward et al. (38) also observed an increase in FKBP4 in breast tumors, which were all estrogen receptor positive; however, estrogen receptor -negative tumors were not tested. It is interesting that in our study, FKBP4 is not methylated in MCF-7 cells whereas is it methylated in MDA-MB-231 cells. It may be possible that FKBP4 methylation affects estrogen receptor expression and may thus have clinical relevance.
In our study, VGF has also proved to be an excellent candidate tumor marker. VGF was methylated in 89% of breast tumors and not in normal tissues. In another study, VGF was down-regulated in MDA-MB-231 after 24 hours of treatment with gemcitabine (accompanied by S-phase arrest) but upregulated after 48 hours of treatment as cells went into apoptosis (40) . Additional studies are needed to determine the role of VGF in cancer pathogenesis and response to various therapies.
Interestingly, WDR45 located on Xp11.23 was found to be methylated in normal breast tissue by bisulfite sequencing. Whereas aberrant methylation of X-chromosome genes can be easily identified in males, detection of methylation of these genes in female cells can be more difficult due to X-chromosome inactivation. Methylation status in breast tumors was not analyzed but methylation of X-chromosome genes in females may be distinguished by more sensitive methods. WD proteins are made up of highly conserved repeating units usually ending with Trp-Asp (WD). They are found in all eukaryotes but not in prokaryotes and regulate cellular functions such as cell division, cell fate determination, gene transcription, transmembrane signaling, mRNA modification, and vesicle fusion (41) . Several human diseases have been recognized due to mutations in WD-repeat proteins (42) . The involvement of WDR45 in breast cancer development remains to be determined.
The new methylation markers FKBP4, MAL, and VGF were studied independently and as a set to examine their role as potential diagnostic markers. Previous studies have shown that when multiple markers are examined as a set, sensitivity increases (6, 27, 43) as we found here. Two previously identified methylation markers (KIF1A and OGDHL; ref. 24) were added to the set to enhance sensitivity. All breast cancer tumors (40 of 40) harbored at least two methylated genes. For example, two breast cancer cases had methylated KIF1A whereas MAL was unmethylated (Table 4 ). In addition, although KIF1A was methylated in two normal breast tissue samples, the other four genes were not methylated in all normal tissues. These five markers seem to function well as a panel with only a minimal decrease in specificity. Methylation of these markers can be detected in all stage I tumors without lymph node metastasis (Table 4) as well as in advanced stages. Therefore, this panel of genes may be used in the development of early detection tests. This panel of genes is methylated in various subtypes of breast cancer: luminal A and B, Her-2 positive, and triple negative, as well as estrogen receptorpositive and estrogen receptor -negative breast cancers (Table 4) , which is the hallmark of a good panel of markers.
There has been much discussion about which genes should be the focus of future efforts for methylation analysis. Our results suggest that many genes not previously confirmed to be involved in tumorigenesis are methylated at significant levels. These novel genes may provide additional clues to pathogenesis.
Finally, the presence of abnormally high DNA concentrations in the sera and plasma of patients with various malignant diseases has been described (44, 45) . Recent publications have shown the presence of promoter hypermethylation of various bodily fluids including serum and nipple aspirate fluid DNA of breast cancer patients (5 -8), which may offer an alternative approach to early detection approaches. Overall, these studies have established an association between the epigenetic alterations found in primary tumor specimens and in plasma, suggesting the potential utility of these alterations as surrogate tumor markers. The newly identified tumor markers here remain to be tested in serum or plasma from breast cancer patients. A blood test for breast cancer based on gene promoter methylation could augment current approaches such as mammography for the early detection of breast cancer.
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